Physician profile
Robert M Dedio
NPI 1073590345
$5,091.14
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,694 · 2020: $119 · 2021: $80.55 · 2022: $1,198.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optinose US, INC. | $3,161.18 | 2019 | |
| Medical Device Business Services, INC. | $774.10 | 2022 | |
| Acclarent, INC | $399.89 | 2019-2022 | |
| Intersect Ent, INC. | $232.45 | 2019 | |
| Genzyme Corporation | $171.11 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $124.74 | 2022 | |
| Sanofi-Aventis U.S. LLC | $99.99 | 2022 | |
| Johnson & Johnson Health Care Systems INC. | $50.88 | 2021 | |
| Alk-Abello, INC | $38.82 | 2019-2020 | |
| Stryker Corporation | $13.76 | 2019 | |
| Cook Medical LLC | $12.54 | 2019 | |
| Novartis Pharmaceuticals Corporation | $11.68 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Dedio listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.